B+
Bull case
25%
Probability
Target price
$78.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
SPRB
Spruce BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
TA-ERT has a defined Q4 2026 BLA target, long-term data described by the company as supporting durable biomarker and cognitive stabilization, and no FDA-approved therapy exists for MPS IIIB. The strengthened balance sheet could support regulatory work and potential launch preparation [#SEC-8K-2026-05-13].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -7.6.
What can break
BLA submission timing, acceptance, and FDA approval are not assured; manufacturing and regulatory execution remain active requirements [#SEC-8K-2026-05-13].
Momentum
84
Value
41
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $48.00 · Bull $78.00 · Bear $25.00Analysis 2026-08-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $147.88
Why
Momentum84 · Δ7d +75.5
Value41 · Δ7d -0.0
Sentiment43 · Δ7d -7.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -7.6.
Contradictions & invalidation
- • BLA submission timing, acceptance, and FDA approval are not assured; manufacturing and regulatory execution remain active requirements [#SEC-8K-2026-05-13].
- • Commercial launch economics, reimbursement, and confirmatory-study execution remain unproven.
- • The thesis remains dependent on submission timing, manufacturing readiness, regulatory review, confirmatory-study planning, and eventual commercial execution.
Catalyst clock
2026-11-02
TA-ERT BLA submission targeted for Q4 2026
Lead driver: Sentiment · See AI snapshot
Momentum
84
9% active weight
Current posture
7d trendImproving
Δ7d
+75.5
Δ21d
+80.9
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
43
62% active weight
Current posture
7d trendSoftening
Δ7d
-7.6
Δ21d
-10.3
Why this grade
Composite grade D. Momentum 84.2 / Value 41.2 / Sentiment 43.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$48.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$152.09M
Beta
3.59
Shares Out
2.87M
P/E (TTM) · Derived
-1.0
P/S (TTM)
126.11
P/FCF (TTM) · Derived
-1.78
Rev YoY
-100.0%
EPS YoY
+90.9%
Gross Margin
+96.4%
Op Margin
-7100.0%
Net Debt
-$48.17M
Current Ratio
9.23
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data